Three International Towers
Level 24 300 Barangaroo Avenue
Sydney, NSW 2000
Full Time Employees:
|Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (||CEO, MD & Exec. Director||674.64k||N/A||1973|
|Ms. Gabrielle Heaton||Director of Fin. & Admin.||186.96k||N/A||N/A|
|Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons)||Company Sec.||100.69k||N/A||1960|
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.